This retrospective study assessed the impact of cabozantinib dose reductions on outcomes in metastatic renal cell carcinoma (mRCC). Patients requiring dose reductions experienced significantly better overall survival and time to treatment failure. These findings underscore the potential of using on-treatment toxicity as an indicator of adequate drug exposure to individualize dosing and optimize treatment effectiveness. Further validation through larger studies is needed.

中文翻译：

---

卡博替尼剂量减少对转移性肾细胞癌 (mRCC) 毒性与临床疗效的关联：来自加拿大肾癌信息系统 (CKCis) 的结果

这项回顾性研究评估了卡博替尼剂量减少对转移性肾细胞癌 (mRCC) 结局的影响。需要减少剂量的患者的总体生存率和治疗失败时间明显延长。这些发现强调了使用治疗毒性作为充分药物暴露指标以实现个体化给药和优化治疗效果的潜力。需要通过更大规模的研究进一步验证。